Pharma Podcasts
Pharma Podcasts
Pharma Pulse
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
In this DDW podcast episode, host Bruno Quinney discusses two recent DDW articles: one on the urgent need to combat antimicrobial resistance (AMR) with insights from Professor Janet Hemingway, and another on the rapid expansion of mRNA therapeutics. Hemingway highlights the growing pipeline of novel antibiotics and vaccines, the challenges SMEs face in clinical development, and the need for stronger incentives to re‑engage big pharma. The mRNA segment outlines how the technology, propelled by COVID‑19 vaccine success, has surged from a $3.4 billion market in 2018 to roughly $40 billion today, with emerging applications in vaccines, cancer, and protein replacement therapies. Both topics underscore how innovative drug discovery is addressing global health threats while confronting funding and regulatory hurdles.
The episode delves into the controversy surrounding the FDA’s handling of hydroxychloroquine during the COVID‑19 pandemic, focusing on whistleblower Dr. Rick Bright’s claims that Dr. Janet Woodcock pressured him to pursue an Emergency Use Authorization (EUA) rather than an expanded‑access protocol....
In this episode of Business Game Changers, host Sarah Westall and Dr. Diane Kayser discuss the rapidly evolving peptide market, focusing on the upcoming weight‑loss peptide retatrutide (also called Reditrutide). They explain how big‑pharma is moving to control peptide supplements,...
In this episode of Touching Base, the Gen editorial team discusses the latest advances in AI for life sciences, including NVIDIA’s GTC announcements on agentic AI, the deployment of 3,500 GPUs by Roche, and the emergence of open‑source autonomous agents...
In this episode, Bruno Quinney highlights three breakthrough studies: Edinburgh researchers engineered E. coli to convert PET plastic waste into the Parkinson's drug L‑DOPA, offering a sustainable route to a vital medication; scientists identified the enzyme DHX8 as a key...
In this episode, attorney Harrison James explains how the Racketeer Influenced and Corrupt Organizations Act (RICO), originally aimed at organized crime, is being used in a landmark civil class action against Takeda Pharmaceuticals and Eli Lilly over the diabetes drug Actos....
In this episode, Immuneering CEO Ben Zeskin explains the company’s novel “deep cyclic inhibition” dosing strategy, which delivers intense, short‑duration MEK inhibition pulses instead of continuous suppression. By restoring the natural intermittent signaling rhythm in healthy cells while repeatedly ambushing...
In this DDW Highlights episode, Bruno Quinney reviews four major stories: a Mayo Clinic study linking the Parkinson's protein alpha‑synuclein to dramatically faster Alzheimer’s progression in women; a Texas A&M‑funded project testing extracellular vesicle (EV) therapy to modulate microglia and...
In this special episode, host Peter Atiyah dives deep into obicetrapib, a CETP inhibitor that lowers LDL‑C and ApoB while raising HDL‑C, and examines its renewed promise in cardiovascular disease and potential Alzheimer’s prevention, especially for APOE‑E4 carriers. He outlines...
In this episode, Daniel Levine interviews Richard Freed, CEO of Rheumagen, about the pivotal role of HLA genes in autoimmune diseases and the company’s innovative gene‑editing approach to cure them. Freed explains how a single amino‑acid change at a conserved...
Gül Dölen, a leading neuroscientist at UC Berkeley and Johns Hopkins, discussed the transformative potential of psychedelic‑assisted therapy during the 2025 Aspen Ideas Festival. Her research demonstrates that compounds such as psilocybin and MDMA can rapidly alleviate treatment‑resistant depression, complex PTSD,...
In this episode, Daniel Levine talks with Feng Nying Zhang, a partner at McKinsey Shanghai, about Asia’s rapid rise as a global hub for biopharmaceutical innovation, highlighted by a McKinsey report showing the region’s share of innovative drug pipelines jumping...
In this episode, Bruno Quinney highlights four major developments: a long‑acting injectable HIV regimen (cabotegravir + rilpivirine) that cut virological failure risk by nearly half versus daily oral therapy; SolasCure’s ORES wound gel, which accelerated debridement 22‑fold and healing seven‑fold in chronic...
In this episode, the hosts dissect why investors misunderstand Hims & Hers' (HEMS) gross margin potential, emphasizing that as a compounder without its own API manufacturing, HEMS cannot achieve margins higher than drug manufacturers. They illustrate how HEMS' margin trajectory...
The episode covers three main business stories: Tamarin Bio’s $13.6M Series A to build an AI model‑coordination platform that makes tools like AlphaFold accessible to wet‑lab biologists; the FDA’s reversal on Moderna’s mRNA‑1010 seasonal flu vaccine, spurring a modest stock...
